论文部分内容阅读
本文前瞻性研究NYHA心功能四级的难治性心衰22例。用多巴酚丁胺(Dobutamine; D)40～60mg/日静滴,连续三日,停药后症状再现改为D40mg、冬眠灵(Wintermine;W)10mg、维脑路通(Venoruton;V)400mg/日静点(下称DWV),分别于两方案用药前半小时及用药后一小时经AZN--Ⅱ型心功能测定仪测定心功能,同时测定斑流变学。结果:两方案治疗后心率均增加,用D和DWV后病人的心率分别由94.07±12.82增至101.028±20.64次/分;95.06±21.06升至104.17±14.29次/分,用药前后及D与
This prospective study of NYHA cardiac function in four refractory heart failure in 22 cases. Dobutamine (D) (Dobutamine 40 ~ 60mg / day intravenous infusion for three consecutive days, after withdrawal of symptoms to D40mg, Winterspring (Wintermine; W) 10mg, Venoruton (Venoruton; V) 400mg / day intravenous injection (hereinafter referred to as DWV), respectively, in the two programs before half an hour and one hour after treatment by the AZN - Ⅱ type of heart function test instrument to measure heart function, while the determination of the stain. Results: After treatment, the heart rate of the two regimens increased. The heart rate of patients after D and DWV increased from 94.07 ± 12.82 to 101.028 ± 20.64 bpm, from 95.06 ± 21.06 to 104.17 ± 14.29 bpm, respectively. Before and after treatment, D and